JPRN-jRCT2080220059未知3 期
Phase III Clinical Study on ART-123 in patients with disseminated intravascular coagulation (DIC) directly caused by malignant hematopoietic tumors or infections
ASAHIKASEI PHARMA CORPORATIO0 个研究点开始时间: 2005年9月8日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- •-Patients given a diagnosis of DIC
- •-Patients with malignant hematopoietic tumors or infections as the underlying diseases which directly caused DIC
- •-Inpatients
- •-Without distinction of sex, etc.
- •Exclusion criteria:
- •-Children under 15, etc.
排除标准
- 未提供
研究者
相似试验
已完成
3 期
Phase III Clinical Study on ART-123 in patients with disseminated intravascular coagulation (DIC) directly caused by malignant hematopoietic tumors or infections (Multicenter double-blind randomized parallel group comparative study with heparin sodium as control drug)Disseminated intravascular coagulation (DIC) directly caused by malignant hematopoietic tumors or infectionsJPRN-C000000327Asahi Kasei Pharma Corporation220
已完成
3 期
Phase III clinical study of ART-123 for the treatment of acute exacerbation of idiopathic pulmonary fibrosisAcute exacerbation of idiopathic pulmonary fibrosis (AE-IPF)JPRN-jRCT2080223271ASAHI KASEI PHARMA CORPORATIO74
未知
4 期
A postmarketing clinical study on ART-123 in patients with DIC caused by solid tumorDisseminated intravascular coagulation (DIC) directly caused by solid tumorJPRN-jRCT1080220847ASAHI KASEI PHARMA CORPORATIO100
暂停
1 期
TAS0313 Phase I/II studySolid tumor (urothelial carcinoma, and so on)JPRN-jRCT2080223768Taiho Pharmaceutical Co., Ltd.130
未知
3 期
Phase 3 clinical study of AK-120 in patients with herpes zosterHerpes zosterJPRN-jRCT2080220058ASAHIKASEI PHARMA CORPORATIO